In general, studies were excluded if they:
did not address the research question;
focused on latent TB (as NAAT for latent TB has already been assessed);
did not provide information on the pre-specified target population (i.e. were focused on mycobacteria that cause Hansen’s disease (leprosy);
did not address one of the pre-specified outcomes and/or provided inadequate data on these outcomes;
were in a language other than English and were of a lower level of evidence than the included studies; or
did not have an appropriate study design.
If the same data were duplicated in multiple articles, only results from the most comprehensive or most recent article were included.
Specified a priori patient subgroups of particular interest in the analysis included patients with high and low pre-test probabilities of having TB and patients with HIV.
Search results
The PRISMA flowcharts are shown in Figure 6, Figure 7, Figure 8, Figure 9 and Figure 10. These outline the study selection process and number of papers considered at each stage of the SR (Liberati et al. 2009).
PRISMA flowcharts Source: Liberati et al. (2009)
evidence, accuracy and change in management)" align="bottom" width="545" height="454" border="0">
Figure 6 Summary of the process used to identify and select studies investigating the use of NAAT to diagnose MTB (direct evidence, accuracy and change in management)
Share with your friends: |